Corten Capital and Ampersand Capital Partners Complete Acquisition of Beacon Intelligence to Accelerate Growth in Life Sciences R&D Intelligence

Corten Capital and Ampersand Capital Partners have completed their acquisition of Beacon Intelligence, a life sciences research and development intelligence provider, from the Hanson Wade Group. This transaction represents Corten Capital II's third investment since closing its €680 million fund in March 2024, positioning the deal as part of a broader growth strategy within the private equity sponsor's life sciences focus.

The acquisition underscores sustained institutional appetite for R&D intelligence assets within the pharmaceutical and biotechnology ecosystems. As drug development timelines and regulatory complexity increase, demand for market intelligence and competitive insights has become integral to life sciences operations. This transaction reflects confidence in the recurring revenue and resilience of data-driven intelligence services.

Corten assumes majority control with Ampersand joining as a minority co-investor, while existing management—led by CEO Rob Poolman and Chair Sati S. Sian—remains in place to execute the next growth phase. Board expansion to include Ampersand's David Anderson signals typical LBO governance structures designed to optimize operational oversight and strategic alignment.

Sector implication: This deal carries limited broad market correlation, as it involves private equity ownership of a specialized intelligence provider. The life sciences sector benefits indirectly from sustained pharmaceutical R&D spending, but the transaction itself is a mid-market PE event with no direct equity market exposure or public company impact.